Recently, I had the high honor and distinct privilege of interviewing Gonzalo Gonzalez, MD Chief of Heart Transplantation and Mechanical Circulatory Support at Baylor University Medical Center in Dallas, TX on #AllThingsCancer, a production of Anti-Cancer Club.
I have 4 take-aways that I’d like to share:
- Heart failure requiring heart transplantation is a potential late effect of some cancer treatments; it does not affect everyone who receives Adriamycin/Doxorubisin, Daunomycin/Daunorubicin, Epirubicin, idarubicin, or mitozantrone +/- chest radiation, or chest radiation alone
- It is not an inevitability; many can be managed medically quite nicely without compromising quality of life
- Although 60% of cancer survivors receive cardiotoxic chemotherapeutic agents, it is the few that will require heart transplant
- Heart transplant is not a cure rather it is the exchange of one set of challenges for another set of challenges, specifically rejection and infection as you enter into the world of immunosuppression for the rest of your life
I am forever thankful to and for Gonzo who upon crossing the threshold of my room would say, “Steph, you’re here and you’re not going anywhere.”
I invite you to watch this clip, then proceed over to the Anti-Cancer Club for watch the duration of the interview as it is must see for every survivor and anyone who loves a survivor.